EPIS B Stock Overview
A medical device company, designs and manufactures implants and surgical instruments in Germany, Sweden, rest of Europe, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Episurf Medical AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.18 |
| 52 Week High | SEK 1.33 |
| 52 Week Low | SEK 0.18 |
| Beta | 1.05 |
| 11 Month Change | -16.29% |
| 3 Month Change | -56.79% |
| 1 Year Change | -84.58% |
| 33 Year Change | -94.85% |
| 5 Year Change | -84.24% |
| Change since IPO | -99.35% |
Recent News & Updates
Recent updates
Shareholders May Be More Conservative With Episurf Medical AB (publ)'s (STO:EPIS B) CEO Compensation For Now
Apr 03
Here's Why Episurf Medical (STO:EPIS B) Must Use Its Cash Wisely
Feb 27Is Episurf Medical (STO:EPIS B) In A Good Position To Invest In Growth?
Nov 09Will Episurf Medical (STO:EPIS B) Spend Its Cash Wisely?
May 03We're Not Very Worried About Episurf Medical's (STO:EPIS B) Cash Burn Rate
Sep 23Episurf Medical (STO:EPIS B) Is In A Good Position To Deliver On Growth Plans
Oct 30We Think Some Shareholders May Hesitate To Increase Episurf Medical AB (publ)'s (STO:EPIS B) CEO Compensation
May 03Pål Ryfors Is The CEO & Sales Director of Episurf Medical AB (publ) (STO:EPIS B) And They Just Picked Up 2.3% More Shares
Feb 21Shareholder Returns
| EPIS B | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -12.0% | -4.0% | -4.3% |
| 1Y | -84.6% | -0.002% | 12.6% |
Return vs Industry: EPIS B underperformed the Swedish Medical Equipment industry which returned -0% over the past year.
Return vs Market: EPIS B underperformed the Swedish Market which returned 12.6% over the past year.
Price Volatility
| EPIS B volatility | |
|---|---|
| EPIS B Average Weekly Movement | 11.1% |
| Medical Equipment Industry Average Movement | 7.1% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: EPIS B's share price has been volatile over the past 3 months.
Volatility Over Time: EPIS B's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 26 | Pal Ryfors | episurf.com |
Episurf Medical AB (publ), a medical device company, designs and manufactures implants and surgical instruments in Germany, Sweden, rest of Europe, the United States, and internationally. It offers Episealer Knee for repairing focal cartilage and bone defects to reduce pain and increase mobility in the patient’s knee joint; Episealer implant, which is designed to fit anatomy and size of the lesion; Episealer toolkit; and Episealer Patellofemoral System, a system to treat osteoarthritis limited to the patellofemoral part of the knee joint. The company also provides Episealer Talus, a solution for the treatment of bone and cartilage defects in the talus bone of the ankle joint; Epioscopy to identify and visualize femoral knee joint cartilage and bone lesions, and tibia, as well as defects on the cruciate ligaments and menisci; Epiguide, a surgical drill guide; and µiFidelity, a web platform for order management, communication, personalized design, and surgical pre-planning.
Episurf Medical AB (publ) Fundamentals Summary
| EPIS B fundamental statistics | |
|---|---|
| Market cap | SEK 117.53m |
| Earnings (TTM) | -SEK 84.70m |
| Revenue (TTM) | SEK 11.70m |
10.0x
P/S Ratio-1.4x
P/E RatioIs EPIS B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EPIS B income statement (TTM) | |
|---|---|
| Revenue | SEK 11.70m |
| Cost of Revenue | SEK 52.40m |
| Gross Profit | -SEK 40.70m |
| Other Expenses | SEK 44.00m |
| Earnings | -SEK 84.70m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 25, 2024
| Earnings per share (EPS) | -0.13 |
| Gross Margin | -347.86% |
| Net Profit Margin | -723.93% |
| Debt/Equity Ratio | 0% |
How did EPIS B perform over the long term?
See historical performance and comparison